Современное состояние проблемы применения антиоксидантов в фармакотерапии болезни Паркинсона

1. Chang K.-H., Chen C.-M. The role of oxidative stress in Parkinson’s disease. Antioxidants. 2020;9(7):597. https://doi.org/10.3390/antiox9070597

2. De Lazzari F., Sandrelli F., Whitworth A.J., Bisaglia M. Antioxidant therapy in Parkinson’s disease: insights from Drosophila melanogaster. Antioxidants. 2020;9(1):52. https://doi.org/10.3390/antiox9010052

3. Bender A., Krishnan K.J., Morris C.M., et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nature Genetics. 2006;38(5):515-7. https://doi.org/10.1038/ng1769

4. Saito Y. D.J.-1. as a biomarker of Parkinson’s disease. DJ-1/PARK7 Protein: Parkinson’s Disease, Cancer and Oxidative Stress-Induced Diseases. 2017:149-71. https://doi.org/10.1007/978-981-10-6583-5_10

5. Hauser D.N., Hastings T.G. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease and monogenic parkinsonism. Neurobiol Dis. 2013;51:35-42. https://doi.org/10.1016/j.nbd.2012.10.011

6. Blesa J., Trigo-Damas I., Quiroga-Varela A., Jackson-Lewis V.R. Oxidative stress and Parkinson’s disease. Front Neuroanat. 2015;9:91. https://doi.org/10.3389/fnana.2015.00091

7. Weng M., Xie X., Liu C., et al. The sources of reactive oxygen species and its possible role in the pathogenesis of Parkinson’s disease. Parkinson’s Disease. 2018;2018(1):9163040. https://doi.org/10.1155/2018/9163040

8. Belarbi K., Cuvelier E., Destée A., et al. NADPH oxidases in Parkinson’s disease: a systematic review. Mol Neurodegener. 2017;12(1):84. https://doi.org/10.1186/s13024-017-0225-5

9. Hartley A., Cooper J., Schapira A. Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson’s disease. Brain Res. 1993;627(2):349-53. https://doi.org/10.1016/0006-8993(93)90341-j

10. Ahlskog J.E. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson’s disease. Mov Disord. 2005;20(3):271-82. https://doi.org/10.1002/mds.20362

11. Grimes J., Hassan M.N., Thakar J.H. Prevention of progression of Parkinson’s disease with antioxidative therapy. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(2-3):165-72. https://doi.org/10.1016/0278-5846(88)90034-6

12. Sofic E., Lange K.W., Jellinger K., Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease. Neurosci Lett. 1992;142(2):128-30. https://doi.org/10.1016/0304-3940(92)90355-b

13. Yoshikawa T. Free radicals and their scavengers in Parkinson’s disease. Eur Neurol. 1993;33(Suppl. 1):60-8. https://doi.org/10.1159/000118539

14. Burkhardt C., Weber H. Parkinson’s disease: a chronic, low-grade antioxidant deficiency? Med Hypotheses. 1994;43(2):111-4. https://doi.org/10.1016/0306-9877(94)90060-4

15. Duarte-Jurado A.P., Gopar-Cuevas Y., Saucedo-Cardenas O., et al. Antioxidant therapeutics in Parkinson’s disease: current challenges and opportunities. Antioxidants. 2021;10(3):453. https://doi.org/10.3390/antiox10030453

16. Bjørklund G., Peana M., Maes M., et al. The glutathione system in Parkinson’s disease and its progression. Neuroscience & Biobehavioral Reviews. 2021;120:470-8. https://doi.org/10.1016/j.neubiorev.2020.10.004

17. Narang J.K., Dogra A., Kaur T., et al. Antioxidants against neurological disorders. Antioxidants: nature’s defense against disease. 2025:285-367. https://doi.org/10.1002/9781394270576.ch9

18. Bassani T.B., Gradowski R.W., Zaminelli T., et al. Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson’s disease model in rats. Brain Res. 2014;1593:95-105. https://doi.org/10.1016/j.brainres.2014.09.068

19. Li Y., Wang S.-M., Guo L., et al. Effects of melatonin levels on neurotoxicity of the medial prefrontal cortex in a rat model of Parkinson’s disease. Chinese Med J. 2017;130(22):2726-31. https://doi.org/10.4103/0366-6999.218025

20. Rasheed M.Z., Andrabi S.S., Salman M., et al. Melatonin improves behavioral and biochemical outcomes in a rotenone-induced rat model of Parkinson’s disease. J Environmental Pathol Toxicol Oncol. 2018;37(2). https://doi.org/10.1615/JEnvironPatholToxicolOncol.2018025666

21. Beal M.F., Matthews R.T., Tieleman A., Shults C.W. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 1998;783(1):109-14. https://doi.org/10.1016/s0006-8993(97)01192-x

22. Horvath T.L., Diano S., Leranth C., et al. Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson’s disease. Endocrinology. 2003;144(7):2757-60. https://doi.org/10.1210/en.2003-0163

23. Bilska A., Dubiel M., Sokołowska-Jez M., et al. Alpha-lipoic acid differently affects the reserpine-induced oxidative stress in the striatum and prefrontal cortex of rat brain. Neuroscience. 2007;146(4):1758-71. https://doi.org/10.1016/j.neuroscience.2007.04.002

24. Zhou L., Cheng Y. Alpha-lipoic acid alleviated 6-OHDA-induced cell damage by inhibiting AMPK/mTOR mediated autophagy. Neuropharmacology. 2019;155:98-103. https://doi.org/10.1016/j.neuropharm.2019.04.009

25. Kulikova O.I., Berezhnoy D.S., Stvolinsky S.L., et al. Neuroprotective effect of the carnosine–α-lipoic acid nanomicellar complex in a model of early-stage Parkinson’s disease. Regul Toxicol Pharmacol. 2018;95:254-9. https://doi.org/10.1016/j.yrtph.2018.03.025

26. Minoia A., Piritore F.C., Bolognin S., et al. Antioxidant, Osteogenic, and Neuroprotective Effects of Homotaurine in Aging and Parkinson’s Disease Models. Antioxidants. 2025;14(3):249. https://doi.org/10.3390/antiox14030249

27. Clark J., Clore E.L., Zheng K., et al. Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in α-synuclein overexpressing mice. PLoS One. 2010;5(8):e12333. https://doi.org/10.1371/journal.pone.0012333

28. Kohen R., Yamamoto Y., Cundy K.C., Ames B.N. Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. Proc Nat Acad Sci. 1988;85(9):3175-9. https://doi.org/10.1073/pnas.85.9.3175

29. Kubota M., Kobayashi N., Sugizaki T., et al. Carnosine suppresses neuronal cell death and inflammation induced by 6-hydroxydopamine in an in vitro model of Parkinson’s disease. PLoS One. 2020;15(10):e0240448. https://doi.org/10.1371/journal.pone.0240448

30. Yuneva A., Kramarenko G., Vetreshchak T., Gallant S., Boldyrev A. Effect of carnosine on Drosophila melanogaster lifespan. Bulletin of Experimental Biology and Medicine. 2002;133:559-61. https://doi.org/10.1023/a:1020273506970

31. Bermúdez M.-L., Seroogy K.B., Genter M.B. Evaluation of carnosine intervention in the Thy1-aSyn mouse model of Parkinson’s disease. Neuroscience. 2019;411:270-8. https://doi.org/10.1016/j.neuroscience.2019.05.026

32. Roghani M., Behzadi G. Neuroprotective effect of vitamin E on the early model of Parkinson’s disease in rat: behavioral and histochemical evidence. Brain Res. 2001;892(1):211-7. https://doi.org/10.1016/s0006-8993(00)03296-0

33. Hernando S., Requejo C., Herran E., et al. Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson’s disease: the role of glia and NRf2 regulation. Neurobiol Dis. 2019;121:252-62. https://doi.org/10.1016/j.nbd.2018.10.001

34. Ono K., Yamada M. Vitamin A potently destabilizes preformed α-synuclein fibrils in vitro: implications for Lewy body diseases. Neurobiol Dis. 2007;25(2):446-54. https://doi.org/10.1016/j.nbd.2006.10.010

35. Gill E.L., Raman S., Yost R.A., et al. l-Carnitine inhibits lipopolysaccharide-induced nitric oxide production of SIM-A9 microglia cells. ACS Cheml Neurosci. 2018;9(5):901-5. https://doi.org/10.1021/acschemneuro.7b00468

36. Zhao Y., Wang Q., Wang Y., et al. Glutamine protects against oxidative stress injury through inhibiting the activation of PI3K/Akt signaling pathway in parkinsonian cell model. Environ Health Prev Med. 2019;24:1-7. https://doi.org/10.1186/s12199-018-0757-5

37. Krishnamoorthy A., Sevanan M., Mani S., et al. Chrysin restores MPTP induced neuroinflammation, oxidative stress and neurotrophic factors in an acute Parkinson’s disease mouse model. Neurosci lett. 2019;709:134382. https://doi.org/10.1016/j.neulet.2019.134382

38. Nguyen T.T., Vuu M.D., Huynh M.A., et al. Curcumin Effectively Rescued Parkinson’s Disease‐Like Phenotypes in a Novel Drosophila melanogaster Model with dUCH Knockdown. Oxid Med Cellular Longev. 2018;2018(1):2038267. https://doi.org/10.1155/2018/2038267

39. Wang Y.-L., Ju B., Zhang Y.-Z., et al. Protective effect of curcumin against oxidative stress-induced injury in rats with Parkinson’s disease through the Wnt/β-catenin signaling pathway. Cell Physiol Biochem. 2017;43(6):2226-41. https://doi.org/10.1159/000484302

40. Mani S., Sekar S., Barathidasan R., et al. Naringenin decreases α-synuclein expression and neuroinflammation in MPTP-induced Parkinson’s disease model in mice. Neurotox Res. 2018;33:656-70. https://doi.org/10.1007/s12640-018-9869-3

41. Sugumar M., Sevanan M., Sekar S. Neuroprotective effect of naringenin against MPTP-induced oxidative stress. Int J Neurosci. 2019;129(6):534-9. https://doi.org/10.1080/00207454.2018.1545772

42. She R., Zhang Z., Han M., et al. Luteolin exhibits anxiolytic and antidepressant potential in Parkinson’s disease rat: antioxidant and anti-inflammatory effects. Rejuvenat Res. 2025;28(2):67-82. https://doi.org/10.1089/rej.2024.0045

43. Medeiros-Linard C.F.B., Andrade-da-Costa B.L.d.S., Augusto R.L., et al. Anacardic acids from cashew nuts prevent behavioral changes and oxidative stress induced by rotenone in a rat model of Parkinson’s disease. Neurotox Res. 2018;34:250-62. https://doi.org/10.1007/s12640-018-9882-6

44. Haddadi R., Poursina M., Zeraati F., Nadi F. Gastrodin microinjection suppresses 6-OHDA-induced motor impairments in parkinsonian rats: insights into oxidative balance and microglial activation in SNc. Inflammopharmacology. 2018;26:1305-16. https://doi.org/10.1007/s10787-018-0470-4

45. Haddadi H., Rajaei Z., Alaei H., Shahidani S. Chronic treatment with carvacrol improves passive avoidance memory in a rat model of Parkinson’s disease. Arquivos de neuro-psiquiatria. 2018;76:71-7. https://doi.org/10.1590/0004-282X20170193

46. Yang C., Mo Y., Xu E., et al. Astragaloside IV ameliorates motor deficits and dopaminergic neuron degeneration via inhibiting neuroinflammation and oxidative stress in a Parkinson’s disease mouse model. Int Immunopharmacol. 2019;75:105651. https://doi.org/10.1016/j.intimp.2019.05.036

47. Li B., Xu P., Wu S., et al. Diosgenin attenuates lipopolysaccharide-induced Parkinson’s disease by inhibiting the TLR/NF-κB pathway. JAlzheimer’s Dis. 2018;64(3):943-55. https://doi.org/10.3233/JAD-180330

48. Zaafan M.A., Abdelhamid A.M., Ibrahim S.M. The protective effect of Korean red ginseng against rotenone-induced Parkinson’s disease in rat model: modulation of nuclear factor-κβ and caspase-3. Curr Pharm Biotechnol. 2019;20(7):588-94. https://doi.org/10.2174/1389201020666190611122747

49. Sharma S., Kumar P., Deshmukh R. Neuroprotective potential of spermidine against rotenone induced Parkinson’s disease in rats. Neurochem Int. 2018;116:104-11. https://doi.org/10.1016/j.neuint.2018.02.010

50. Катунина Е., Титова Н., Малыхина Е. и др. Оксидантный стресс и болезнь Паркинсона: механизмы и терапевтические перспективы. Журнал неврологии и психиатрии им. C.C. Корсакова. 2015;115(7):141-5.

51. Bashkatova V., Narkevich V., Vitskova G., Vanin A. The influence of anticonvulsant and antioxidant drugs on nitric oxide level and lipid peroxidation in the rat brain during penthylenetetrazole-induced epileptiform model seizures. Prog NeuroPsychopharmacol Biol Psychiatry. 2003;27(3):487-92. https://doi.org/10.1016/S0278-5846(03)00037-X

52. Дюмаев К., Воронина Т., Смирнов Л. Антиоксиданты в профилактике и терапии патологий ЦНС. М., 1995.

53. Щулькин А.В. Влияние мексидола на развитие феномена эксайтотоксичности нейронов in vitro. Журнал неврологии и психиатрии им. C.C. Корсакова. 2012;112(2):35-9.

54. Усанова А.А., Инчина В.И., Зорькина А.В. Цитопротекторы в коррекции сочетанных метаболических нарушений. 2009.

55. Oyovwi M.O., Chijiokwu E.A., Ben-Azu B., et al. Potential roles of natural antioxidants in modulating neurodegenerative disease pathways. Mol Neurobiol. 2025;62(8):10367-97. https://doi.org/10.1007/s12035-025-04874-w

56. Bala M. Concerted action of Nrf2-ARE pathway, MRN complex, HMGB1 and inflammatory cytokines-implication in modification of radiation damage. Redox Biol. 2014;2:832-46. https://doi.org/10.1016/j.redox.2014.02.008

57. Gureev A.P., Chernyshova E.V., Krutskikh E.P., et al. Role of the Nrf2/ARE Pathway in the mtDNA Reparation. Fronti Biosci (Landmark edition). 2024;29(6):218. https://doi.org/10.31083/j.fbl2906218

58. Xu L.-L., Wu Y.-F., Yan F., et al. 5-(3, 4-Difluorophenyl)-3-(6-methylpyridin-3-yl)-1, 2, 4-oxadiazole (DDO-7263), a novel Nrf2 activator targeting brain tissue, protects against MPTP-induced subacute Parkinson’s disease in mice by inhibiting the NLRP3 inflammasome and protects PC12 cells against oxidative stress. Free Radic Biol Med. 2019;134:288-303. https://doi.org/10.1016/j.freeradbiomed.2019.01.003

59. Lee J.A., Son H.J., Choi J.W., et al. Activation of the Nrf2 signaling pathway and neuroprotection of nigral dopaminergic neurons by a novel synthetic compound KMS99220. Neurochem Int. 2018;112:96-107. https://doi.org/10.1016/j.neuint.2017.11.006

60. Guo X., Han C., Ma K., et al. Hydralazine protects nigrostriatal dopaminergic neurons from MPP+ and MPTP induced neurotoxicity: Roles of Nrf2-ARE signaling pathway. Front Neurol. 2019;10:271. https://doi.org/10.3389/fneur.2019.00271

61. Ira Shoulson M., Group P.S. DATATOP: a decade of neuroprotective inquiry. Ann Neurol. 1998;44:S160-S6.

62. Zhang S., Hernan M., Chen H., et al. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology. 2002;59(8):1161-9. https://doi.org/10.1212/01.wnl.0000028688.75881.12

63. Miller III E.R., Pastor-Barriuso R., Dalal D., et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Int Med. 2005;142(1):37-46. https://doi.org/10.7326/0003-4819-142-1-200501040-00110

64. Miyake Y., Fukushima W., Tanaka K., et al. Dietary intake of antioxidant vitamins and risk of Parkinson’s disease: a case–control study in Japan. Eur J Neurol. 2011;18(1):106-13. https://doi.org/10.1111/j.1468-1331.2010.03088.x

65. de Rijk M.C., Breteler M.M., den Breeijen J.H., et al. Dietary antioxidants and Parkinson disease: the Rotterdam Study. Arch Neurol. 1997;54(6):762-5. https://doi.org/10.1001/archneur.1997.00550180070015

66. Etminan M., Gill S.S., Samii A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: a meta-analysis. Lancet Neurol. 2005;4(6):362-5. https://doi.org/10.1016/S1474-4422(05)70097-1

67. Schirinzi T., Martella G., Imbriani P., et al. Dietary vitamin E as a protective factor for Parkinson’s disease: clinical and experimental evidence. Front Neurol. 2019;10:148. https://doi.org/10.3389/fneur.2019.00148

68. Fahn S. A pilot trial of high‐dose alpha‐tocopherol and ascorbate in early Parkinson’s disease. Ann Neurol. 1992;32(S1):S128-S32. https://doi.org/10.1002/ana.410320722

69. Morens D., Grandinetti A., Waslien C., et al. Case‐control study of idiopathic Parkinson’s disease and dietary vitamin E intake. Neurology. 1996;46(5):1270-. https://doi.org/10.1212/wnl.46.5.1270

70. Scheider W., Hershey L., Vena J., et al. Dietary antioxidants and other dietary factors in the etiology of Parkinson’s disease. Mov Disord. 1997;12(2):190-6. https://doi.org/10.1002/mds.870120209

71. Hellenbrand W., Boeing H., Robra B.-P., et al. Diet and Parkinson’s disease II: A possible role for the past intake of specific nutrients: Results from a self-administered food-frequency questionnaire in a case-control study. Neurology. 1996;47(3):644-50. https://doi.org/10.1212/wnl.47.3.644

72. Hughes K.C., Gao X., Kim I.Y., et al. Intake of antioxidant vitamins and risk of Parkinson’s disease. Mov Disord. 2016;31(12):1909-14. https://doi.org/10.1002/mds.26819

73. Yeum K.J., Russell R.M., Krinsky N.I., Aldini G. Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. Arch Biochem Biophys. 2004;430(1):97-103. https://doi.org/10.1016/j.abb.2004.03.006

74. Becker B.F. Towards the physiological function of uric acid. Free Radic Biol Med. 1993;14(6):615-31. https://doi.org/10.1016/0891-5849(93)90143-i

75. Hink H.U., Santanam N., Dikalov S., et al. Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol. 2002;22(9):1402-8. https://doi.org/10.1161/01.atv.0000027524.86752.02

76. Davies K.J., Sevanian A., Muakkassah-Kelly S.F., Hochstein P. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J. 1986;235(3):747-54. https://doi.org/10.1042/bj2350747

77. Cipriani S., Desjardins C.A., Burdett T.C., et al. Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson’s disease. PLoS One. 2012;7(5):e37331. https://doi.org/10.1371/journal.pone.0037331

78. de Lau L.M., Koudstaal P.J., Hofman A., Breteler M.M. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol. 2005;58(5):797-800. https://doi.org/10.1002/ana.20663

79. Ascherio A., LeWitt P.A., Xu K., et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009;66(12):1460-8. https://doi.org/10.1001/archneurol.2009.247

80. Coolen E.J., Arts I.C., Bekers O., et al. Oral bioavailability of ATP after prolonged administration. Br J Nutr. 2011;105(3):357-66. https://doi.org/10.1017/S0007114510003570

81. Bhattacharyya S., Bakshi R., Logan R., et al. Oral I nosine P ersistently E levates P lasma antioxidant capacity in P arkinson’s disease. Mov Disord.2016;31(3):417-21. https://doi.org/10.1002/mds.26483

82. Schwarzschild M.A., Macklin E.A., Bakshi R., et al. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. 2019;93(14):e1328-e38. https://doi.org/10.1212/WNL.0000000000008194

83. Snow B.J., Rolfe F.L., Lockhart M.M., et al. A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson’s disease. Mov Disord. 2010;25(11):1670-4. https://doi.org/10.1002/mds.23148

84. Mischley L.K. Glutathione in Parkinson’s disease. 2016.

85. Garcia-Moreno J.C., de la Riva M.P., Martínez-Lara E., et al. Tyrosol, a simple phenol from EVOO, targets multiple pathogenic mechanisms of neurodegeneration in a C. elegans model of Parkinson’s disease. Neurobiol Aging. 2019;82:60-8. https://doi.org/10.1016/j.neurobiolaging.2019.07.003

86. Sechi G., Deledda M.G., Bua G., et al. Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20(7):1159-70. https://doi.org/10.1016/s0278-5846(96)00103-0

87. Hauser D.N., Dukes A.A., Mortimer A.D., Hastings T.G. Dopamine quinone modifies and decreases the abundance of the mitochondrial selenoprotein glutathione peroxidase 4. Free Radic Biol Med. 2013;65:419-27. https://doi.org/10.1016/j.freeradbiomed.2013.06.030

88. Mischley L.K., Vespignani M.F., Finnell J.S. Safety survey of intranasal glutathione. J Altern Complement Med. 2013;19(5):459-63. https://doi.org/10.1089/acm.2011.0673

89. Mischley L.K., Leverenz J.B., Lau R.C., et al. A randomized, double‐blind phase I/II a study of intranasal glutathione in P arkinson’s disease. Mov Disord. 2015;30(12):1696-701. https://doi.org/10.1002/mds.26351

90. Mischley L.K., Lau R.C., Shankland E.G., et al. Phase IIb study of intranasal glutathione in Parkinson’s disease. J Parkinson’s Dis. 2017;7(2):289-99. https://doi.org/10.3233/JPD-161040

91. Wei C.-C., Chang C.-H., Liao V.H.-C. Anti-Parkinsonian effects of β-amyrin are regulated via LGG-1 involved autophagy pathway in Caenorhabditis elegans. Phytomedicine. 2017;36:118-25. https://doi.org/10.1016/j.phymed.2017.09.002

92. Boldyrev A., Fedorova T., Stepanova M., et al. Carnisone Increases Efficiency of DOPA Therapy of Parkinson’s Disease: A Pilot Study. Rejuvenation Res. 2008;11(4):821-7. https://doi.org/10.1089/rej.2008.0716

93. Федорова Т.Н., Багыева Г.Х., Степанова М.С. и др. Эффективность карнозина при болезни Паркинсона. Неврологический вестник. 2009;41(1):24-9.

94. Танашян М., Лагода О., Федин П. и др. Антиоксидантная терапия хронических цереброваскулярных заболеваний. Русский медицинский журнал. 2010;10(6):1-3.

95. Федин А., Захаров В., Танашян М., Чуканова Е. и др. Результаты международного многоцентрового рандомизированного двойного слепого плацебоконтролируемого исследования оценки эффективности и безопасности последовательной терапии пациентов с хронической ишемией мозга препаратами Мексидол и Мексидол ФОРТЕ 250 (исследование МЕМО). Журнал неврологии и психиатрии им. С.С. Корсакова. 2021;121(11):7-16.

96. Катунина Е., Малыхина Е., Кузнецов Н. и др. Антиоксиданты в комплексной терапии болезни Паркинсона. Журнал неврологии и психиатрии. 2006;106(9):22-8.

97. Benfeito S., Oliveira C., Soares P., et al. Antioxidant therapy: Still in search of the ‘magic bullet’. Mitochondrion. 2013;13(5):427-35. https://doi.org/10.1016/j.mito.2012.12.002

98. Myung S.-K., Kim Y., Ju W., et al. Effects of antioxidant supplements on cancer prevention: meta-analysis of randomized controlled trials. Ann Oncol. 2010;21(1):166-79. https://doi.org/10.1093/annonc/mdp286

99. Jeon Y.-J., Myung S.-K., Lee E.-H., et al. Effects of beta-carotene supplements on cancer prevention: meta-analysis of randomized controlled trials. Nutr Cancer. 2011;63(8):1196-207. https://doi.org/10.1080/01635581.2011.607541

100. Liu Z.-Q. Antioxidants may not always be beneficial to health. Nutrition. 2014;30(2):131-3. https://doi.org/10.1016/j.nut.2013.04.006

101. Percário S., da Silva Barbosa A., Varela E.L..P, et al. Oxidative stress in Parkinson’s disease: Potential benefits of antioxidant supplementation. Oxid Med Cell Longev. 2020;2020(1):2360872. https://doi.org/10.1155/2020/2360872

102. Ahmad B., Masoud M.S., Ashfaq U.A., et al. Clinical Use of Antioxidants for the Treatment of Brain Disorders. The Role of Natural Antioxidants in Brain Disorders: Springer; 2023. P. 269-83.

103. Davies A.M., Holt A.G. Why antioxidant therapies have failed in clinical trials. J Theor Biol. 2018;457:1-5. https://doi.org/10.1016/j.jtbi.2018.08.014